StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Oncology Portfolio — International net revenues by Year

Oncology Portfolio — International net revenues ($M) ($M)

AbbVie Oncology Portfolio — International net revenues: $2,575M in FY2025, up 10.2% from a year earlier. That is the highest of the 8 years on record here.

Latest, FY2025
2,575
Period ended Dec 31, 2025
Change on a year earlier
+10.2%
2,336 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Oncology | 4,080 | 2,575 | 6,655 | (3.3) | 10.3 | 1.5 | 9.9 | 1.4”

Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up oncology Portfolio — International net revenues

Cite this data

StockData. (2026). AbbVie Oncology Portfolio — International net revenues ($M), annual FY2018–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-onc-intl

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.